Feb 20, 2024 / 08:00AM GMT
Fredrik Alpsten - Devyser Diagnostics AB - CEO
And again, welcome to the Devyser Q4 2023 earnings call. It's really a pleasure to have you all here. Today, you will listen to me, I'm Fredrik Alpsten, the Devyser's CEO; and our Chief Commercial Officer, Theis Kipling. I have also asked Sabina Berlin, our CFO, to join us during the Q&A session.
Before we go into the Q4 figures and talk about the nice development we are seeing, I want to take 4 minutes of your time to repeat for our new potential shareholders what Devyser is. Devyser is becoming increasingly well-known as a reliable, high-quality, next-generation sequencing reagent provider. Through our collaboration with Thermo Fisher, our name and brand are getting a lot of additional recognition.
Devyser was founded and driven by the value of first and accurate diagnosis. It's the foundation for everything we do to ensure every patient has access to a correct diagnosis in the shortest possible time. Genetic tests can still require a very long time for patients before they get their results, causing worry and potential harm to
Q4 2023 Devyser Diagnostics AB Earnings Call Transcript
Feb 20, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers